Recent studies suggest that the effects of KRAS on redox homoeostasis are required for maintaining the cancer phenotype and may thus represent attractive therapeutic targets for KRAS-driven cancers, which still represent a clinical challenge due to the lack of effective therapies. This evidence concerns the gene KRAS and cancer.